You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
暗盤盤中 | 鷹瞳科技-B、三葉草生物-B輝立暗盤跌5.26%、跌2.84%,富途暗盤跌4.13%、跌2.84%

11月4日,鷹瞳科技-B(02251)輝立暗盤下跌5.26%,報於71.15港元,成交額7480萬港元;富途暗盤下跌4.13%,報於72港元,成交額285.68萬港元。發行價爲75.1港元。

公司簡介:鷹瞳Airdoc是全球視網膜影像人工智能領域的領導者和先行者,公司基於視網膜影像人工智能識別的早期檢測、輔助診斷及健康風險評估解決方案,通過視網膜影像、多模態數據分析以及人工智能深度學習算法,改善了慢性病傳統的早期檢測及診斷方式,在醫療機構和大健康場景中實現對慢性病的無創、精確、快速、高性價比且大規模的診斷及相關健康風險評估。

三葉草生物-B(02197)輝立暗盤下跌2.84%,報於13港元,成交額1310萬港元;富途暗盤下跌2.84%,報於13港元,成交額839.38萬港元。發行價爲13.38港元。

公司簡介:全球性的臨牀階段生物技術公司,致力於開發新型疫苗及生物治療候選產品,解決全球最危及生命的疾病及公共衛生威脅。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account